Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature

Suda, Kentaro; Inoshita, Naoko; Iguchi, Genzo; Fukuoka, Hidenori; Takahashi, Michiko; Nishizawa, Hitoshi; Yamamoto, Masaaki; Yamada, Shozo; Takahashi, Yutaka

doi:10.1507/endocrj.ej12-0272

Cited by 51 publications

(19 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, the addition of CAB to the treatment of these patients has been proposed and has been reported in eight studies ( Table 1); none of these studies was a randomized or placebo-controlled trial [6,[22][23][24][25][26][27][28]. The maximal duration of follow-up was 24 months.…”

Section: Cab In Conjunction With Ssasmentioning

confidence: 99%

Cabergoline treatment in acromegaly: cons

Kasuki

Neto

2014

Endocrine

View full text Add to dashboard Cite

Many options are available for the treatment of acromegaly, including surgery, radiotherapy, and medical treatment. Cabergoline (CAB), a dopamine agonist with high affinity for dopamine receptor type 2, has been used both in monotherapy and in conjunction with somatostatin analogs (SSAs). Although it is administered orally and has a relatively lower-cost in comparison with SSAs, few studies have demonstrated its usefulness, there is a lack of randomized-controlled trials and other drugs (SSAs and pegvisomant) with more data in the literature are available; these issues are the main drawbacks of adopting CAB for the treatment of acromegaly.

show abstract

Section: Cab In Conjunction With Ssasmentioning

confidence: 99%

Cabergoline treatment in acromegaly: cons

Kasuki

Neto

2014

Endocrine

View full text Add to dashboard Cite

show abstract

“…Immunohistochemistry for paraffin-embedded tumor samples was performed by using avidin-biotinperoxidase complex (ABC) as previously described [13]. The following primary antibody were used: AIP (HPA004063, SIGMA-ALDRICH, U.S.A.), E-cadherin, somatostatin receptor subtype 2 and 5 (SSTR2, 5) (SS-800 and SS-838, Gramsch Lab., Germany), and dopamine D2 receptor (D2R).…”

Section: Immunohistochemistrymentioning

confidence: 99%

Genetic and clinical characteristics of Japanese patients with sporadic somatotropinoma

Matsumoto

Izawa²,

Fukuoka

et al. 2016

Endocr J

Self Cite

View full text Add to dashboard Cite

“…Over the past 6 years, 8 independent studies [38][39][40][41][42][43][44][45] (Table 3) have reported on the impact of CAB in patients with acromegaly. Only 2 studies 38,39 systematically investigated the effects of CAB on the development of CRVD in patients with acromegaly, whereas the remaining 6 studies [40][41][42][43][44][45] reported no change in echocardiographic findings, 40 no development of new valvular abnormalities, 41 or no data.…”

Section: Cabergoline and Cardiac Valvulopathy In Acromegalymentioning

confidence: 99%

“…Only 2 studies 38,39 systematically investigated the effects of CAB on the development of CRVD in patients with acromegaly, whereas the remaining 6 studies [40][41][42][43][44][45] reported no change in echocardiographic findings, 40 no development of new valvular abnormalities, 41 or no data. [42][43][44][45] Moreover, patient series are not homogeneous across studies, as they have included acromegalic patients receiving either CAB monotherapy 38,39,42,45 and combined to somatostatin analogs 41,43 or pegvisomant. 40,44 Nonclinically relevant valve regurgitations have been reported in 26.2% 38 and 50.4% 39 of patients, and included mild mitral regurgitation in 19.0% 38 and 9.6%, 39 whereas mild tricuspid regurgitation accounted for 7.1% 38 and 23.5% 39 of cases.…”

Section: Cabergoline and Cardiac Valvulopathy In Acromegalymentioning

confidence: 99%